论文部分内容阅读
目的探讨奥拉西坦联合瑞舒伐他汀对脑梗死患者血清超敏C反应蛋白(hs-CRP)、血小板聚集率(PAG)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)及核转录因子(NF-κB)水平的影响。方法选取2013年1月至2014年12月吉林省人民医院收治的脑梗死住院患者90例为研究对象,按随机数字表法分为观察组和对照组,每组45例。观察组患者采用奥拉西坦联合瑞舒伐他汀治疗,对照组患者给予常规治疗,比较两组患者治疗前后hs-CRP、PAG、IL-1β、IL-6及NF-κB水平变化及临床疗效。结果对照组患者的治疗有效率为71.1%(32/45),观察组患者的治疗有效率为93.3%(42/45),差异有统计学意义(P<0.05);治疗前两组患者的hs-CRP、PAG、IL-1β、IL-6及NF-κB水平及神经功能缺损评分无明显差异,治疗后两组患者上述指标均较治疗前明显改善,且观察组较对照组改善更明显,差异有统计学意义(P<0.05)。结论采用奥拉西坦联合瑞舒伐他汀治疗脑梗死患者能够显著改善血清hs-CRP、PAG、IL-1β、IL-6及NF-κB水平,改善神经功能缺损状态,提高治疗效果。
Objective To investigate the effects of oxiracetam combined with rosuvastatin on serum hs-CRP, PAG, IL-1β, (IL-6) and nuclear factor (NF-κB) levels. Methods Ninety hospitalized patients with cerebral infarction who were admitted to Jilin Provincial People’s Hospital from January 2013 to December 2014 were selected as study subjects and divided into observation group and control group according to random number table method, with 45 cases in each group. Patients in the observation group were treated with oxiracetam combined with rosuvastatin, and patients in the control group were given routine treatment. The changes of hs-CRP, PAG, IL-1β, IL-6 and NF-κB levels and the clinical effects were compared between the two groups before and after treatment . Results The effective rate of treatment was 71.1% (32/45) in the control group and 93.3% (42/45) in the observation group, the difference was statistically significant (P <0.05) hs-CRP, PAG, IL-1β, IL-6 and NF-κB levels and neurological deficit scores were not significantly different after treatment in both groups were significantly improved than those before treatment, and the observation group improved more significantly than the control group , The difference was statistically significant (P <0.05). Conclusions Oxiracetam combined with rosuvastatin can significantly improve the serum levels of hs-CRP, PAG, IL-1β, IL-6 and NF-κB in patients with cerebral infarction, improve the neurological deficits and improve the therapeutic effect.